

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (hi-05) FRENLOSIRSEN SODIUM

PRONUNCIATION fren" loe sir' sen

THERAPEUTIC CLAIM Treatment of multiple myeloma


CHEMICAL NAMES

1. DNA, d(*P*-thio)([2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)- α -l-mannofurano]A-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)- α -l-mannofurano]G-T-T-G-T-A-A-A-T-G-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m⁵rU-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)- α -l-mannofurano]m⁵C-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)- α -l-mannofurano]G), sodium salt (1:15) (CAS INDEX NAME)

2. *all-P-ambo*-2'-O,4'-C-[(1*S*)-ethane-1,1-diyl]-*P*-thioadenylyl-(3'→5')-2'-O,4'-C-[(1*S*)-ethane-1,1-diyl]-*P*-thioguanlylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanlylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanlylyl-(3'→5')-2'-O-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-*P*-thioguanlylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-O,4'-C-[(1*S*)-ethane-1,1-diyl]-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-O,4'-C-[(1*S*)-ethane-1,1-diyl]guanosine, sodium salt (1:15) (IUPAC NAME)

STRUCTURAL FORMULA

SEQ 1 agttgtaaat gagucg



MOLECULAR FORMULA C₁₇₇H₂₁₁N₆₃Na₁₅O₈₉P₁₅S₁₅

MOLECULAR WEIGHT 5935.4 Da

TRADEMARK None as of yet

SPONSOR Ionis Pharmaceuticals

CODE DESIGNATIONS ION-935918; ION251

CAS REGISTRY NUMBER 2304711-82-6

UNII J2MMX1VR5I

BWW